Prosecution Insights
Last updated: October 27, 2026
Application No. 18/254,897

COMPOUNDS HAVING INHIBITORY EFFECT ON MITOCHONDRIAL HYPERFISSION

Non-Final OA §102
Filed
May 30, 2023
Priority
Nov 30, 2020 — JP 2020-198084 +1 more
Examiner
ROZOF, TIMOTHY R
Art Unit
1625
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Kyushu University, National University Corporation
OA Round
3 (Non-Final)
73%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
96%
With Interview

Examiner Intelligence

Grants 73% — above average
73%
Career Allowance Rate
708 granted / 974 resolved
+12.7% vs TC avg
Strong +23% interview lift
Without
With
+23.3%
Interview Lift
resolved cases with interview
Fast prosecutor
2y 0m
Avg Prosecution
49 currently pending
Career history
1021
Total Applications
across all art units

Statute-Specific Performance

§101
2.5%
-37.5% vs TC avg
§103
21.4%
-18.6% vs TC avg
§102
32.9%
-7.1% vs TC avg
§112
25.6%
-14.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 974 resolved cases

Office Action

§102
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION This is a response to Applicant’s communication filed on August 28, 2026. Application No. 18/254,897, is a 371 of PCT/JP2021/043654, filed November 29, 2021, and claims foreign priority to Japanese application No. JAPAN 2020-198084, filed November 30, 2020. In a preliminary amendment filed May 30, 2023, Applicant added new claims 12-20. In amendment filed August 28, 2026, Applicant cancelled claims 5 and 8. Claims 2, 3, and 12-20 are currently withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected species. The election was made without traverse in the reply filed on November 7, 2025. Claims 1, 4, 6, 7, and 9-11 examined below. Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on August 28, 2026, has been entered. Rejection Withdrawn The rejection of claims 1, 4, and 6-11 under 35 U.S.C. 102(a)(1) as being anticipated by Bossert et al., DE 2228377, is withdrawn in view of Applicant’s August 28, 2026, Amendment & Remarks. The rejection of claim 5 under 35 U.S.C. 112(b) as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor regards as the invention, in view of Applicant’s August 28, 2026, Amendment & Remarks. New Rejection Necessitated by the August 28, 2026, Amendment & Remarks Claim Rejections - 35 USC § 102(a)(1) The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1, 4, 6, 7, and 9-11 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Hisaki et al., U.S. Patent No. 4,874,773. The CAS Abstract for Hisaki discloses the following compound and pharmaceutical compositions thereof: PNG media_image1.png 280 570 media_image1.png Greyscale (Hisaki et al., citing the CAS Abstract for the compound depicted above; see also Hisaki et al., ‘773 patent, Col. 10, ln. 39-Col. 16, ln. 68, Examples 1-56, and Table 2, for other examples.) The above compound reads on a compound of formula (3), wherein formula (3) one of R1 and R1’ is a hydrogen the other is a cycloalkyl; X is O; R2 is a lower cycloalkyl; one of R3 or R4 is a nitro and the other is hydrogen; and R5 and R6 are both methyl. Pharmaceutical compositions of the compounds disclosed there are prepared as antihypertensives in the treatment of cardiac disorders. Conclusion No claims are allowed. Contact Information Any inquiry concerning this communication or earlier communications from the examiner should be directed to TIMOTHY R ROZOF whose telephone number is (571)270-5992. The examiner can normally be reached on Monday - Friday, 9:00 a.m. -5:00 p.m.. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew Kosar can be reached on (571) 272-0913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /TIMOTHY R ROZOF/ Primary Examiner, Art Unit 1625
Read full office action

Prosecution Timeline

May 30, 2023
Application Filed
Jan 23, 2026
Non-Final Rejection mailed — §102
Apr 22, 2026
Response Filed
Jun 03, 2026
Final Rejection mailed — §102
Aug 28, 2026
Request for Continued Examination
Aug 31, 2026
Response after Non-Final Action
Sep 30, 2026
Non-Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12759980
COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE, MYODEGENERATIVE, AND LYSOSOMAL STORAGE DISORDERS
4y 2m to grant Granted Oct 13, 2026
Patent 12751935
METHOD OF TREATING, AMELIORATING AND/OR PREVENTING DEPRESSION
3y 5m to grant Granted Oct 06, 2026
Patent 12751954
Methods For Treating Drug and Vaccine Induced Immune Thrombocytopenia by Administering Specific Compounds
2y 11m to grant Granted Oct 06, 2026
Patent 12746234
USE OF COMPOSITION CONTAINING CILOSTAZOL IN CEREBROVASCULAR DISEASES
3y 2m to grant Granted Sep 29, 2026
Patent 12741951
IMPROVED CHLORANTRANILIPROLE PROCESS THROUGH USE OF A CRYSTAL INTERMEDIATE
3y 8m to grant Granted Sep 22, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
73%
Grant Probability
96%
With Interview (+23.3%)
2y 0m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 974 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month